Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


06.10.2025

1 Am J Pathol
3 Anticancer Res
2 BJU Int
4 BMC Cancer
2 BMC Urol
1 Cancer Imaging
1 Cancer Lett
1 Cancer Res
13 Eur Urol
5 Int J Radiat Oncol Biol Phys
4 Int J Urol
2 J Clin Oncol
11 J Nucl Med
2 J Urol
1 Lancet Oncol
1 Oncology
6 Prostate
2 Urol Int
3 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Pathol

  1. ALBANESE C, Rodriguez OC
    From The American Journal of Pathology's Archives: Pioneering Studies on the Mechanisms of Metastatic Prostate Cancer.
    Am J Pathol. 2025;195:1756-1757.
    PubMed        


    Anticancer Res

  2. YUMISAKI H, Kubo N, Oike T, Kawamura H, et al
    A Dosimetric Evaluation of the Feasibility and Robustness of Ultra-hypofractionated Carbon Ion Radiotherapy Planning for the Treatment of Prostate Cancer.
    Anticancer Res. 2025;45:4453-4464.
    PubMed         Abstract available

  3. IMAFUKU H, Terashima K, Fukunishi K, Suefuji H, et al
    Carbon-Ion Radiotherapy for Prostate Cancer in Hemodialysis Patients.
    Anticancer Res. 2025;45:4465-4472.
    PubMed         Abstract available

  4. LEHRER S, Rheinstein PH
    PROX1 Expression Is Significantly Associated With ERG Expression and the TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Anticancer Res. 2025;45:4381-4388.
    PubMed         Abstract available


    BJU Int

  5. BONADDIO J, Carll J, Eapen R, Sathianathen N, et al
    The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer.
    BJU Int. 2025 Sep 30. doi: 10.1111/bju.70015.
    PubMed         Abstract available

  6. SCUDERI S, Gandaglia G, Briganti A, Montorsi F, et al
    Re: 'Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review'.
    BJU Int. 2025 Oct 3. doi: 10.1111/bju.70024.
    PubMed        


    BMC Cancer

  7. SEVEN D, Dalan AB, Bayrak OF
    Targeting GSTM3 for therapeutic potential in advanced prostate cancer.
    BMC Cancer. 2025;25:1493.
    PubMed         Abstract available

  8. JIN L, Ma Z, Gao F, Li M, et al
    Automated machine learning for prostate cancer detection and Gleason score prediction using T2WI: a diagnostic multi-center study.
    BMC Cancer. 2025;25:1483.
    PubMed         Abstract available

  9. KIM JK, Park MU, Lee D, Kim HJ, et al
    Sustained PSA screening is associated with downstaging and improved survival in prostate cancer: a 12-year Korean cohort study.
    BMC Cancer. 2025;25:1462.
    PubMed         Abstract available

  10. JIN Y, Zhang Y, Wang M, Bai X, et al
    Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto((R))) in advanced prostate cancer: a disproportionality analysis based on the fda's adverse event reporting system (FAERS).
    BMC Cancer. 2025;25:1470.
    PubMed         Abstract available


    BMC Urol

  11. LI Y, Pan D, Wang Z, Ji J, et al
    The diagnostic value of urinary exosomes in prostate cancer: a prospective multicenter study.
    BMC Urol. 2025;25:246.
    PubMed         Abstract available

  12. IKEDA M, Uemura K, Ito Y, Ito H, et al
    Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer.
    BMC Urol. 2025;25:235.
    PubMed         Abstract available


    Cancer Imaging

  13. MIN K, Lin Q, Qiu D
    Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers.
    Cancer Imaging. 2025;25:116.
    PubMed         Abstract available


    Cancer Lett

  14. AHMAD G, El Sadda R, Botchkina G, Ojima I, et al
    Corrigendum to "Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 Inhibits prostate cancer stem cell-induced tumor growth" [Cancer Lett. 2017 Aug 11;406:71-80].
    Cancer Lett. 2025 Sep 23:218043. doi: 10.1016/j.canlet.2025.218043.
    PubMed        


    Cancer Res

  15. ALHOURANI F, Tauziet M, Ayeul M, Dambrun P, et al
    Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer.
    Cancer Res. 2025 Oct 1. doi: 10.1158/0008-5472.CAN-24-3974.
    PubMed         Abstract available


    Eur Urol

  16. LIU H, Sun F, Wu J
    Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. In press. https://doi.org/10.1016/j.e
    Eur Urol. 2025 Sep 27:S0302-2838(25)04691-3. doi: 10.1016/j.eururo.2025.
    PubMed        

  17. STABILE A, Montorsi F
    Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. In press. https://doi.org/10.1016/j.e
    Eur Urol. 2025 Sep 23:S0302-2838(25)04641-X. doi: 10.1016/j.eururo.2025.09.4128.
    PubMed        

  18. GINSBURG KB, Zamani A, Borza T
    Re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. In press. https:/
    Eur Urol. 2025 Sep 24:S0302-2838(25)04647-0. doi: 10.1016/j.eururo.2025.
    PubMed        

  19. PALMSTEDT E, Hugosson J, Arnsrud Godtman R
    Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extende
    Eur Urol. 2025 Sep 24:S0302-2838(25)04644-5. doi: 10.1016/j.eururo.2025.09.4130.
    PubMed        

  20. CONTEDUCA V, Bruno G, Landriscina M
    Reconciling Clinical and Molecular Heterogeneity in Metastatic Castration-resistant Prostate Cancer: The Promise of Integrated Prognostic Models.
    Eur Urol. 2025 Sep 27:S0302-2838(25)04676-7. doi: 10.1016/j.eururo.2025.09.4140.
    PubMed        

  21. ARTAMONOVA N, Heidegger I
    Re: Pao-Hwa Lin, Alanna D. Burwell, Edward L. Giovannucci, et al. Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials. Eur Urol. In press. https://doi.org/10.1
    Eur Urol. 2025 Sep 27:S0302-2838(25)04697-4. doi: 10.1016/j.eururo.2025.09.4147.
    PubMed        

  22. WANG Y, Lu Q, Zhao X
    Re: Lars Holmberg, Hans Garmo, Sven-Olov Andersson, et al. Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2
    Eur Urol. 2025 Sep 27:S0302-2838(25)04696-2. doi: 10.1016/j.eururo.2025.
    PubMed        

  23. BERNARDINO RM, van der Kwast T, Fleshner NE
    Reply to Nour Khalil, Guiseppe Maiolino, and Eric Barret's Letter to the Editor re: Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner. Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives. Eu
    Eur Urol. 2025 Sep 27:S0302-2838(25)04689-5. doi: 10.1016/j.eururo.2025.09.4146.
    PubMed        

  24. STRAUSS AS, Cleves A, Dahm P
    Re: Elio Mazzone, Alice Thomson, David C. Chen, et al. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer Aft
    Eur Urol. 2025 Sep 26:S0302-2838(25)04651-2. doi: 10.1016/j.eururo.2025.09.4131.
    PubMed        

  25. MONTORSI F, Zaurito P, Gandaglia G
    Re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol 2025;88:167-75.
    Eur Urol. 2025 Sep 26:S0302-2838(25)04685-8. doi: 10.1016/j.eururo.2025.
    PubMed        

  26. FISHER DJ, Burdett S, Vale CL
    Reply to Shenglong Li and Cuicui Wang's Letter to the Editor re: Sarah Burdett, David J. Fisher, Jayne F. Tierney, et al. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Sy
    Eur Urol. 2025 Sep 25:S0302-2838(25)04653-6. doi: 10.1016/j.eururo.2025.
    PubMed        

  27. MONTIRONI R, Cimadamore A, Lopez-Beltran A, Cheng L, et al
    Re: Lucia L. Rijstenberg, Hridya Harikumara, Esther I. Verhoef, et al. Identification of Intraductal-to-Invasive Spatial Transitions in Prostate Cancer: Proposal for a New Unifying Model on Intraductal Carcinogenesis. Histopathology 2025;86:1091-100.
    Eur Urol. 2025 Sep 25:S0302-2838(25)04656-1. doi: 10.1016/j.eururo.2025.
    PubMed        

  28. MISZCZYK M, Sanchez-Salas R, Emberton M, Shariat SF, et al
    Re: Karolina Menne Guricova, Cedric Draulans, Floris J. Pos, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial. J Clin Oncol. In press. https:/
    Eur Urol. 2025 Sep 24:S0302-2838(25)04650-0. doi: 10.1016/j.eururo.2025.09.4133.
    PubMed        


    Int J Radiat Oncol Biol Phys

  29. COOPER S, Westley RL, Biscombe K, Dunlop A, et al
    HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;123:773-782.
    PubMed         Abstract available

  30. YAZDANI E, Sadeghi M, Karamzade-Ziarati N, Jabari P, et al
    Machine Learning-based Dose Prediction in [(177)Lu]Lu-PSMA-617 Therapy by Integrating Biomarkers and Radiomic Features from [(68)Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography.
    Int J Radiat Oncol Biol Phys. 2025;123:891-908.
    PubMed         Abstract available

  31. LUDDY KA, West J, Robertson-Tessi M, Desai B, et al
    Evolutionary double-bind treatment using radiotherapy and NK cell-based immunotherapy in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2025 Sep 23:S0360-3016(25)06293.
    PubMed         Abstract available

  32. YU JB, DeStephano DM, Jeffers B, Tward AE, et al
    The Comparative Toxicity of Focal Ablation vs. IMRT for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Sep 23:S0360-3016(25)06282.
    PubMed         Abstract available

  33. ONAL C, Guler OC, Torun N, Demirhan B, et al
    Gallium-68-Labeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Response in Pelvic Node-Positive Prostate Cancer After Definitive Radiation Therapy: Prognostic Implications.
    Int J Radiat Oncol Biol Phys. 2025 Jul 17:S0360-3016(25)04496.
    PubMed         Abstract available


    Int J Urol

  34. SUZUKI K, Khan N, Taguchi T, Hattori K, et al
    Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
    Int J Urol. 2025 Oct 3. doi: 10.1111/iju.70235.
    PubMed         Abstract available

  35. SASAKI T, Higashi S, Nishikawa T, Sugino Y, et al
    Short-Term Longitudinal Changes in Quality of Life Among Japanese Patients With Prostate Cancer After Single-Port Robot-Assisted Radical Prostatectomy: A Preliminary Prospective Study.
    Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70251.
    PubMed        

  36. YASUDA Y, Yoshida S, Matsubara D, Takahara T, et al
    Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70253.
    PubMed        

  37. DENIZ ME, Gur G, Kayra MV, Hasbay B, et al
    PSMA PET/CT and Multiparametric MRI in Assessing Local Extension and Lymph Node Metastasis in Prostate Cancer.
    Int J Urol. 2025 Sep 24. doi: 10.1111/iju.70239.
    PubMed         Abstract available


    J Clin Oncol

  38. LI J, Huang R, Hu H
    Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.
    J Clin Oncol. 2025 Oct 3:JCO2501476. doi: 10.1200/JCO-25-01476.
    PubMed        

  39. TRAN PT, Wang JH, Tang C, Kiess AP, et al
    Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.
    J Clin Oncol. 2025 Oct 3:JCO2501855. doi: 10.1200/JCO-25-01855.
    PubMed        


    J Nucl Med

  40. HOYVIK AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, et al
    Optimizing [(212)Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts.
    J Nucl Med. 2025 Oct 3:jnumed.125.270444. doi: 10.2967/jnumed.125.270444.
    PubMed         Abstract available


  41. Biomarkers in Prostate Cancer: What's in the Blood?
    J Nucl Med. 2025;66:6A.
    PubMed        

  42. LIU F, Monterosso ME, Boucher D, Shakti S, et al
    Preclinical Evaluation of [(212)Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen-Targeted alpha-Therapy for Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.269707. doi: 10.2967/jnumed.125.269707.
    PubMed         Abstract available

  43. HADASCHIK B, Gillessen S, Sartor O
    (177)Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270836. doi: 10.2967/jnumed.125.270836.
    PubMed        

  44. GIRI VK, Kolodny GM, Garnick MB
    First-Line [(177)Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270704. doi: 10.2967/jnumed.125.270704.
    PubMed         Abstract available

  45. PEPIN A, Doucette A, Vapiwala N, Narayan VK, et al
    Safety of the Combination of External Beam Radiotherapy with (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Sep 25:jnumed.125.270316. doi: 10.2967/jnumed.125.270316.
    PubMed         Abstract available

  46. ALTUNAY B, Schafer L, Morgenroth A, Pena Q, et al
    Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy.
    J Nucl Med. 2025 Aug 28:jnumed.125.270317. doi: 10.2967/jnumed.125.270317.
    PubMed         Abstract available

  47. TEUNISSEN FR, Oprea-Lager DE, Peters SMB, Smeenk RJ, et al
    Current Developments in Combining External-Beam Radiotherapy and (177)Lu-Labeled PSMA Ligands for Prostate Cancer Treatment.
    J Nucl Med. 2025 Oct 3:jnumed.125.270465. doi: 10.2967/jnumed.125.270465.
    PubMed         Abstract available

  48. SARTOR O, Emmett L, Herrmann K
    Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer.
    J Nucl Med. 2025 Oct 3:jnumed.125.271144. doi: 10.2967/jnumed.125.271144.
    PubMed        

  49. KUCUK NO, Coskun N, Araz M, Alan Selcuk N, et al
    Initial Multicenter Experience with [(161)Tb]Tb-PSMA in [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results.
    J Nucl Med. 2025 Oct 3:jnumed.125.270952. doi: 10.2967/jnumed.125.270952.
    PubMed         Abstract available

  50. KARMANN A, Rose S, Herrmann K, Kratochwil C, et al
    alpha-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer.
    J Nucl Med. 2025 Oct 3:jnumed.125.270940. doi: 10.2967/jnumed.125.270940.
    PubMed        


    J Urol

  51. MOSER AM, Elanjian A, Zamani A, Ginsburg KB, et al
    The risk of clinically significant prostate cancer on subsequent biopsies in men with HGPIN/ASAP on an MRI-informed index biopsy.
    J Urol. 2025 Sep 29:101097JU0000000000004797. doi: 10.1097/JU.0000000000004797.
    PubMed        

  52. BORGES RC, Tourinho-Barbosa RR, Dias N, de Barros Pena Ribeiro Paiva G, et al
    Detection of Clinically Significant Prostate Cancer Using Micro-Ultrasound Versus MRI/Ultrasound Fusion Biopsy: A Propensity-Weighted Comparative Study.
    J Urol. 2025 Sep 26:101097JU0000000000004793. doi: 10.1097/JU.0000000000004793.
    PubMed         Abstract available


    Lancet Oncol

  53. SPRATT DE, Schaeffer EM
    Revisiting prostate cancer active surveillance candidacy.
    Lancet Oncol. 2025;26:1273-1275.
    PubMed        


    Oncology

  54. DI LORENZO G, Verde A, Scafuri L, Baio R, et al
    Development and validation of the PREVES-HOR Questionnaire: a patient-reported measure of hormone-therapy-related quality of life in prostate-cancer patients undergoing androgen-deprivation therapy.
    Oncology. 2025 Sep 29:1-29. doi: 10.1159/000548317.
    PubMed         Abstract available


    Prostate

  55. YAZGAN SC, Bolek H, Coskunpinar M, Yekeduz E, et al
    Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration-Sensitive Prostate Cancer.
    Prostate. 2025 Sep 24. doi: 10.1002/pros.70062.
    PubMed         Abstract available

  56. QIONG L, Qingyi L, Bohong G, YouCheng H, et al
    Influence of 5-Alpha Reductase Inhibitors on PI-RADS Scores and Prostate Cancer Detection: A Systematic Review and Meta-Analysis.
    Prostate. 2025 Sep 28. doi: 10.1002/pros.70066.
    PubMed         Abstract available

  57. FEDELE N, Wilson RJ, Doherty J, Baxi P, et al
    Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate-Resistant Prostate Cancer.
    Prostate. 2025 Sep 28. doi: 10.1002/pros.70060.
    PubMed         Abstract available

  58. HAN D, Jiang C, Liu H, Ye D, et al
    MEIS2 Modulates Oxidative Phosphorylation and ROS Generation to Affect CD8(+) T Cell Antitumor Immunity in Prostate Cancer.
    Prostate. 2025 Oct 1. doi: 10.1002/pros.70051.
    PubMed         Abstract available

  59. TANG Z, Guo P, Liu Y
    LIAS Promotes Cuproptosis in Prostate Cancer Cells by Suppressing Glycolysis via the p53 Signaling Pathway.
    Prostate. 2025 Oct 1. doi: 10.1002/pros.70049.
    PubMed         Abstract available

  60. SAKAMOTO S, Zhao X, Onozawa M, Shiota M, et al
    Impact of Human Development Index Category on Prostate Cancer Characteristics in Asia.
    Prostate. 2025 Oct 1. doi: 10.1002/pros.70050.
    PubMed         Abstract available


    Urol Int

  61. BAHLBURG H, Bahlburg H, Rausch P, Silberg M, et al
    Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: Fact or Fiction?
    Urol Int. 2025;109:501-507.
    PubMed         Abstract available

  62. SCHMITZ-DRAGER BJ, Schmitz-Drager BJ, Bismarck E, Ebert T, et al
    Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN).
    Urol Int. 2025;109:519-527.
    PubMed         Abstract available


    Urology

  63. HANDA N, Kaul H, Neill C, Proudfoot JA, et al
    A novel application of Decipher testing in HoLEP specimens for risk stratification of incidentally detected prostate cancer.
    Urology. 2025 Oct 1:S0090-4295(25)00937-9. doi: 10.1016/j.urology.2025.
    PubMed         Abstract available

  64. VAFAEI E
    Editorial Comment on "Economic Burden of Urinary Incontinence in Men with Prostate Cancer: Results from the Medical Expenditure Panel Survey (2016-2021)".
    Urology. 2025 Sep 26:S0090-4295(25)00911-2. doi: 10.1016/j.urology.2025.
    PubMed        

  65. MAY M, Wolff I, Burger M, Brookman-May S, et al
    Letter to the Editor on "Impact of Age, Marital Status, Smoking, and Alcohol Consumption on Urinary and Sexual Function in Prostate Cancer Patients Treated With Radical Prostatectomy: A Prospective Cohort Study".
    Urology. 2025 Sep 23:S0090-4295(25)00900-8. doi: 10.1016/j.urology.2025.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.